Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 6, Issue 1, Pages 18-20
Clinical Gastroenterology

5-ASA Suppositories in Hemorrhoidal Disease

P Gionchetti, M Campieri, A Belluzzi, C Brignola, M Miglioli, and L Barbara

Policlinico S Orsola–Istituto di Clinica Medica e Gastroenterologia–Via Massarenti, 9-40100 Bologna, Italy

Received 1 October 1991; Revised 6 November 1991

Copyright © 1992 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Forty patients with active hemorrhoidal disease were entered into this double-blind trial, 20 of whom were randomized to treatment with 5-aminosalicylic acid (5-ASA) (500 mg) suppositories. Clinical and sigmoidoscopic assessment was carried out before the start of the trial and after two weeks of treatment. At the end of the study, 5-ASA suppositories showed results superior to those of placebo for all parameters evaluated (P<0.01). There were no adverse events reported related to the use of suppositories. 5-ASA suppositories are a valid therapeutic approach for hemorrhoidal disease as it reduces the intensity of all symptoms and significantly decreases congestion of the hemorrhoidal plexus.